The Food and Drug Administration (FDA) has approved Fetroja (cefiderocol; Shionogi) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The treatment is indicated for patients aged ≥18 years with limited or no alternative…
A history of kidney stones among patients undergoing percutaneous coronary intervention is associated with higher in-hospital mortality and 1- and 3-year myocardial infarctions risks.
The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ATM-AVI (aztreonam and avibactam; Allergan) for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). Aztreonam is a monobactam that has activity against metallo β-lactamase…
A high dose and continuous infusion of cefoxitin has been associated with clinical success in treating febrile urinary tract infections in men caused by extended spectrum beta-lactamase–producing E coli.
Active surveillance (AS) is an appropriate management strategy for black men with favorable-risk prostate cancer (PCa) who adhere to a standardized protocol of regular PSA tests and biopsies, investigators reported. The prospective, multi-institutional cohort Canary Prostate Cancer Active Surveillance Study (PASS), which included 1315 men on AS, found that black men were at no higher…
